Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 43 of 45

Conclusions (4 of 4)

Disease-modifying anti-rheumatic drugs (DMARDs) of both classes are associated with well-known adverse effects (toxicity of oral DMARDs, serious infections with biologic DMARDs), but the comparative risks are not known.

Overall tolerability is similar between DMARDs of both classes. The evidence about cancer risk is limited, but the risk for patients with rheumatoid arthritis does not appear to be elevated by DMARDs of either class.